Market Overview:
Gemcabene calcium is expected to account for a major share of this market owing to its high efficacy and safety profile.
Product Definition:
The drug helps to reduce the amount of cholesterol in the blood by blocking its production and absorption.
Gemcabene Calcium:
MGL-3196:
The normal function of this gene is to produce an enzyme called apolipoprotein B which helps in transporting cholesterol and other lipids in the blood cells.
Application Insights:
The other applications include research settings and private practices. The hospital segment dominated the overall market in terms of revenue in 2017 owing to an increase in prevalence of cardiovascular diseases that require treatment with statins. According to data published by WHO, around 1 billion people have Cardiovascular Diseases (CVDs) globally which is expected to rise by 2030 leading to increased demand for effective cholesterol-lowering therapies thus driving the growth of this segment over the forecast period.
The Clinic application was estimated as largest revenue generating segment owing to increasing awareness about HFC among patients coupled with growing adoption of these drugs due largely its low cost coupled with gemcabene calcium being a generic drug available under different brand names such as Zomacton amongst others which makes it easily affordable for most families across globe thereby driving its consumption within this application setting over forecast period.
Regional Analysis:
North America dominated the global market in 2017. Moreover, favorable government initiatives for R&D investments and commercialization of novel therapeutics are some other factors contributing to the growth of this regional market.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising disposable income levels and improving healthcare infrastructure in emerging countries such as China & India. Growing geriatric population prone to cardiovascular diseases will also drive demand for cholesterol-lowering drugs in this region during the forecast period.
Growth Factors:
- Increasing prevalence of heterozygous familial hypercholesterolemia (FH)
- Growing awareness about the benefits of early diagnosis and treatment of heterozygous familial hypercholesterolemia (FH)
- Rising demand for novel and more effective therapies for heterozygous familial hypercholesterolemia (FH)
- Technological advancements in the field of diagnostics and therapeutics for heterozygous familial hypercholesterolemia (FH)
- increasing number of clinical studies on new drugs for the treatment of heterozygous familial hypercholesterolemia
Scope Of The Report
Report Attributes
Report Details
Report Title
Heterozygous Familial Hypercholesterolemia Drug Market Research Report
By Type
Gemcabene Calcium, MGL-3196, ST-103, Others
By Application
Clinic, Hospital, Others
By Companies
Daewoong Co Ltd, Esperion Therapeutics Inc, Gemphire Therapeutics Inc, Madrigal Pharmaceuticals Inc, Daewoong Co Ltd
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
213
Number of Tables & Figures
150
Customization Available
Yes, the report can be customized as per your need.
Global Heterozygous Familial Hypercholesterolemia Drug Market Report Segments:
The global Heterozygous Familial Hypercholesterolemia Drug market is segmented on the basis of:
Types
Gemcabene Calcium, MGL-3196, ST-103, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinic, Hospital, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Daewoong Co Ltd
- Esperion Therapeutics Inc
- Gemphire Therapeutics Inc
- Madrigal Pharmaceuticals Inc
- Daewoong Co Ltd
Highlights of The Heterozygous Familial Hypercholesterolemia Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Gemcabene Calcium
- MGL-3196
- ST-103
- Others
- By Application:
- Clinic
- Hospital
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Heterozygous Familial Hypercholesterolemia Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Heterozygous familial hypercholesterolemia (HH) is a genetic disorder that causes high levels of cholesterol in the blood. People with HH have two copies of the defective gene for low-density lipoprotein (LDL) cholesterol, which makes it difficult for their bodies to break down LDL cholesterol. This can lead to an increased risk of heart disease and stroke. Some people with HH take medications to lower their LDL cholesterol levels. These medications include statins, which are drugs that work by blocking the action of enzymes that help make LDL cholesterol. Other people with HH may need to follow a special diet or take other supplements to lower their LDL cholesterol levels.
Some of the major companies in the heterozygous familial hypercholesterolemia drug market are Daewoong Co Ltd, Esperion Therapeutics Inc, Gemphire Therapeutics Inc, Madrigal Pharmaceuticals Inc, Daewoong Co Ltd.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Heterozygous Familial Hypercholesterolemia Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Heterozygous Familial Hypercholesterolemia Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Heterozygous Familial Hypercholesterolemia Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Heterozygous Familial Hypercholesterolemia Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Heterozygous Familial Hypercholesterolemia Drug Market Size & Forecast, 2020-2028
4.5.1 Heterozygous Familial Hypercholesterolemia Drug Market Size and Y-o-Y Growth
4.5.2 Heterozygous Familial Hypercholesterolemia Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Gemcabene Calcium
5.2.2 MGL-3196
5.2.3 ST-103
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Clinic
6.2.2 Hospital
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Heterozygous Familial Hypercholesterolemia Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Heterozygous Familial Hypercholesterolemia Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Gemcabene Calcium
9.6.2 MGL-3196
9.6.3 ST-103
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Clinic
9.10.2 Hospital
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Gemcabene Calcium
10.6.2 MGL-3196
10.6.3 ST-103
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Clinic
10.10.2 Hospital
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Gemcabene Calcium
11.6.2 MGL-3196
11.6.3 ST-103
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Clinic
11.10.2 Hospital
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Gemcabene Calcium
12.6.2 MGL-3196
12.6.3 ST-103
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Clinic
12.10.2 Hospital
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Gemcabene Calcium
13.6.2 MGL-3196
13.6.3 ST-103
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Clinic
13.10.2 Hospital
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Heterozygous Familial Hypercholesterolemia Drug Market: Competitive Dashboard
14.2 Global Heterozygous Familial Hypercholesterolemia Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Daewoong Co Ltd
14.3.2 Esperion Therapeutics Inc
14.3.3 Gemphire Therapeutics Inc
14.3.4 Madrigal Pharmaceuticals Inc
14.3.5 Daewoong Co Ltd
